KRAS and colorectal carcinoma: KRAS-mutant CRC cells exhibit reduced aspartate but elevated asparagine levels, adapting to glutamine deprivation via PI3K-AKT-mTOR-mediated activation of asparagine synthetase (ASNS) (166).